May 26, 2015 — At EuroPCR 2015, Mitralign presented updates on its mitral and tricuspid valve repair systems, including a presentation on six-month data on its Mitral system.
The Mitralign Percutaneous Annuloplasty System (MPAS) is not approved for sale or distribution; however it is currently being evaluated in clinical trials for a CE mark indication. The MPAS for tricuspid regurgitation is not approved for sale or distribution, but is anticipated to begin clinical investigation in 2015.
Updates on Mitralign’s percutaneous programs were available in the following presentations:
- Transcatheter mitral valve therapies; new rings, anchors, and techniques;
- First-in-man of a transcatheter tricuspid valve in a severely regurgitant tricuspid valve patient;
- Mitralign procedure: A step-by-step case demonstration; and
- Cardiovascular innovation pipeline – Mitral and tricuspid valve intervention.
Georg Nickenig, M.D., presented “Mitralign CE mark six month data” during the Mitralign Symposium, chaired by Azeem Latib, M.D., and Ted Feldman, M.D. Nickenig was joined by Joachim Schofer, M.D., and Rebecca Hahn, M.D., providing their experience with the Mitralign Percutaneous Annuloplasty System for tricuspid regurgitation.
Unlike other approaches, the Mitralign Percutaneous Annuloplasty System uses wires and catheters to deliver pledgets to create plications and tighten the annulus, reduce valve circumference and bring the leaflets closer together.
For more information: www.mitralign.com
November 03, 2026 
